TDR Research Rates Trulieve Cannabis A 'Buy', Potential 46% Stock Price Upside
Portfolio Pulse from Nicolás Jose Rodriguez
TDR Research has rated Trulieve Cannabis (OTC:TCNNF) a 'Buy', citing strong financial health and growth potential. The report projects a 46% upside in stock price, with 2024 revenue estimates of $1.20 billion and an EBITDA of $298.8 million. Despite some challenges, anticipated regulatory changes in the cannabis industry could further enhance Trulieve's prospects.
May 30, 2024 | 6:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TDR Research has rated Trulieve Cannabis a 'Buy', projecting a 46% upside in stock price. The company shows strong financial health with 2024 revenue estimates of $1.20 billion and an EBITDA of $298.8 million. Anticipated regulatory changes could further enhance its prospects.
The 'Buy' rating from TDR Research, along with a projected 46% upside, indicates strong investor confidence. The company's robust financial metrics and potential regulatory changes in the cannabis industry further support a positive short-term impact on the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100